The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | IMPROVE-MF: imetelstat and ruxolitinib in patients with myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the IMPROVE-MF study (NCT04576156), which evaluates the combination of imetelstat, a telomerase inhibitor, and ruxolitinib in patients with myelofibrosis (MF) who have a suboptimal response to ruxolitinib. Dr Mascarenhas highlights the potential of combining these two drugs to synergize and bring the treatment earlier in the disease, with preclinical data suggesting a promising outcome. The IMPROVE-MF study is a Phase Ib trial that assesses different doses and cohorts of imetelstat administered intravenously with a stable dose of ruxolitinib every four weeks. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
